EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access

Precision Reprogramming in CAR-T Cell Therapy: Innovations, Challenges, and Future Directions of Advanced Gene Editing

Zimo Jia, Jiajin Wu, Jiyue Zhang, Peixian Zheng, Haoxuan Zhang, Yiqin Lin, Tao Pan, Meng Wu, Yuqin Song

International Journal of Biological Sciences · 24.10.2025 · 21 (15) · 6884-6906

DOI: 10.7150/ijbs.124144 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift International Journal of Biological Sciences, erschienen am 24.10.2025. Verfasst von Zimo Jia und 8 weiteren Autor:innen. Beteiligte Einrichtung: Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education), Department of Lymphoma, Peking University Cancer Hospital & Inst…. Hauptthemen laut MEDLINE: Gene Editing, Immunotherapy, Adoptive, Receptors, Chimeric Antigen. Die Arbeit wurde bisher 5-mal zitiert (Crossref). Der Volltext ist frei in PubMed Central verfügbar.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Chimeric antigen receptor (CAR)-T cell therapy represents a breakthrough in cancer immunotherapy, demonstrating impressive clinical outcomes, particularly for hematologic malignancies. However, its broader therapeutic application, especially against solid tumors, remains limited. Key challenges include T cell exhaustion, limited persistence, cytokine-mediated toxicities, and logistical hurdles associated with manufacturing autologous products. Emerging gene editing technologies, such as CRISPR/Cas systems, base editing, and prime editing, offer novel approaches to optimize CAR-T cells, aiming to enhance efficacy while managing toxicity and improving accessibility. This review comprehensively examines the current landscape of these gene editing tools in CAR-T cell therapy, highlighting the latest advancements, persisting challenges, and future directions. Leveraging gene editing holds the potential to transform CAR-T therapy into a more potent, safer, and broadly applicable modality for cancer and beyond.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Gene EditingImmunotherapy, AdoptiveReceptors, Chimeric AntigenHumansCRISPR-Cas SystemsNeoplasmsT-LymphocytesAnimals

Stichwörter der Autor:innen

CAR-TCRISPR/Cas9gene editingimmunotherapy

Substanzen

Receptors, Chimeric Antigen

Autor:innen und Institutionen

  • Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education), Department of Lymphoma, Peking University Cancer Hospital & Institute. Beijing 100142, China.

Zitieren

APA

Jia, Z., Wu, J., Zhang, J., Zheng, P., Zhang, H., Lin, Y., Pan, T., Wu, M., & Song, Y. (2025). Precision Reprogramming in CAR-T Cell Therapy: Innovations, Challenges, and Future Directions of Advanced Gene Editing. International Journal of Biological Sciences, 21(15), 6884-6906. https://doi.org/10.7150/ijbs.124144

Vancouver

Jia Z, Wu J, Zhang J, Zheng P, Zhang H, Lin Y, et al. Precision Reprogramming in CAR-T Cell Therapy: Innovations, Challenges, and Future Directions of Advanced Gene Editing. International Journal of Biological Sciences. 2025;21(15):6884-6906. doi:10.7150/ijbs.124144

BibTeX
@article{Jia2025,
  author = {Jia, Zimo and Wu, Jiajin and Zhang, Jiyue and Zheng, Peixian and Zhang, Haoxuan and Lin, Yiqin and Pan, Tao and Wu, Meng and Song, Yuqin},
  title = {Precision Reprogramming in CAR-T Cell Therapy: Innovations, Challenges, and Future Directions of Advanced Gene Editing},
  journal = {International Journal of Biological Sciences},
  year = {2025},
  volume = {21},
  number = {15},
  pages = {6884--6906},
  doi = {10.7150/ijbs.124144}
}
Kostenlos starten →